StockNews.com Begins Coverage on Calithera Biosciences (NASDAQ:CALA)
by Renee Jackson · The Cerbat GemStockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Calithera Biosciences Stock Performance
NASDAQ:CALA opened at $0.01 on Wednesday. Calithera Biosciences has a 12-month low of $0.00 and a 12-month high of $0.12. The business has a 50 day simple moving average of $0.01 and a 200 day simple moving average of $0.02.
About Calithera Biosciences
Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.
See Also
- Five stocks we like better than Calithera Biosciences
- 10 Best Airline Stocks to Buy
- Texas Roadhouse Stock Steering for New Highs This Year
- How Investors Can Find the Best Cheap Dividend Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What Investors Need to Know About Upcoming IPOs
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity